Long-term COVID-19 vaccine- and Omicron infection-induced humoral and cell-mediated immunity




Belik, Milja; Reinholm, Arttu; Kolehmainen, Pekka; Heroum, Jemna; Maljanen, Sari; Altan, Eda; Österlund, Pamela; Laine, Larissa; Ritvos, Olli; Pasternack, Arja; Naves, Rauno A.; Iakubovskaia, Alina; Barkoff, Alex-Mikael; He, Qiushui; Lempainen, Johanna; Tähtinen, Paula A.; Ivaska, Lauri; Jalkanen, Pinja; Julkunen, Ilkka; Kakkola, Laura

PublisherFrontiers Media SA

2024

Frontiers in Immunology

Frontiers in Immunology

Front Immunol

15

1664-3224

DOIhttps://doi.org/10.3389/fimmu.2024.1494432

https://doi.org/10.3389/fimmu.2024.1494432

https://research.utu.fi/converis/portal/detail/Publication/477187887



INTRODUCTION: Mutations occurring in the spike (S) protein of SARS-CoV-2 enables the virus to evade COVID-19 vaccine- and infection-induced immunity.

METHODS: .Here we provide a comprehensive analysis of humoral and cell-mediated immunity in 111 healthcare workers who received three or four vaccine doses and were followed up to 12 and 6 months, respectively, after the last vaccine dose. Omicron breakthrough infection occurred in 71% of the vaccinees, enabling evaluation of vaccine- and vaccine/infection-induced hybrid immunity.

RESULTS: Neutralizing antibodies were the highest against the ancestral D614G and were sequentially reduced against the Omicron variants BA.2, BA.5 and XBB.1.5. S1-specific IgG and neutralizing antibody levels were significantly higher in infected than in uninfected vaccinees, and the fourth vaccine dose in combination with a breakthrough infection resulted in high neutralizing antibody levels against all variants. T cell-mediated immunity, instead, was well retained already after two vaccine doses, and was not significantly strengthened by additional booster vaccine doses or Omicron breakthrough infections.

DISCUSSION: While humoral immunity is sensitive to mutations in the S protein and thus declined rapidly, the cell-mediated immunity is durable to antigenic variation, which may explain the good efficacy of COVID-19 vaccines against a severe disease.


The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Academy of Finland (grant number 337530 to IJ, 339512 to LK), Jane and Aatos Erkko Foundation (grant numbers 3067-84b53 and 5360-cc2fc to IJ) and the Sigrid Jusélius Foundation (to IJ and LK).


Last updated on 2025-31-03 at 11:08